You just read:

Respira Therapeutics Regains North America Rights from United Therapeutics to Phase 2 Inhaled Drug-Device Product, RT234, for Pulmonary Hypertension Indications

News provided by

Respira Therapeutics

Oct 10, 2019, 08:30 ET